{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:46:59Z","timestamp":1775911619389,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To analyze the 2-year clinical outcomes after photodynamic therapy\u2013induced acute exudative maculopathy (PAEM) in patients with chronic central serous chorioretinopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Prospective observational study that included 64 eyes of 64 patients with chronic central serous chorioretinopathy who received half-fluence photodynamic therapy and had a 2-year follow-up. Patients were classified into two groups based on whether they had had PAEM at 3 days after treatment (PAEM+, n = 22; \u226550 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m) increase in subretinal fluid or not (PAEM\u2212, n = 42). Best-corrected visual acuity and subretinal fluid changes evaluated with optical coherence tomography were registered at 3 days, 1 month, 3 months, 1 year, and 2 years after photodynamic therapy. The number of recurrences, the appearance of outer retinal atrophy, and choroidal neovascularization were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Best-corrected visual acuity was 75.9 \u00b1 13.6 (20\/32) and 82.0 \u00b1 11.0 letters (20\/25) at 2 years in the PAEM+ and PAEM\u2212 groups, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.055). There were no differences in the best-corrected visual acuity change (4.2 \u00b1 7.7 vs. 3.3 \u00b1 7.1 letters; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.654) and the subretinal fluid decrease (\u2212117.3 \u00b1 74.2 vs. \u2212138.5 \u00b1 83.6 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.323) at 2 years between patients with and without PAEM. No differences in the number of recurrences (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.267), the appearance of choroidal neovascularization (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.155), or outer retinal atrophy (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.273) between both groups were noted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Patients with chronic central serous chorioretinopathy with and without PAEM presented similar results at 2 years in best-corrected visual acuity gain, subretinal fluid reduction, and complication rate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003876","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T20:48:31Z","timestamp":1687553311000},"page":"1988-1995","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["TWO-YEAR CLINICAL OUTCOMES AFTER PHOTODYNAMIC ACUTE EXUDATIVE MACULOPATHY IN PATIENTS WITH CHRONIC CENTRAL SEROUS CHORIORETINOPATHY"],"prefix":"10.1097","volume":"43","author":[{"given":"Jos\u00e9 Ignacio","family":"Fern\u00e1ndez-Vigo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"},{"name":"Department of Ophthalmology, Centro Internacional de Oftalmolog\u00eda Avanzada, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Moreno-Morillo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Burgos-Blasco","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Ly-Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Oribio-Quinto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Garc\u00eda-Caride","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Donate-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria (IdISSC), Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","first-page":"198","article-title":"Treatment of age-related macular degeneration with photodynamic therapy TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajo.2012.06.027","article-title":"Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy","volume":"155","author":"Yamashita","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0974-9233.106400","article-title":"Transient increased exudation after photodynamic therapy of intraocular tumors","volume":"20","author":"Mashayekhi","year":"2013","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","article-title":"Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level","volume":"87","author":"Chan","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2020.04.022","article-title":"Choroidal anatomic alterations after photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study","volume":"217","author":"Iovino","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.2147\/OPTH.S359302","article-title":"Photodynamic therapy-induced acute exudative maculopathy (PAEM): prevalence, impact and management strategies","volume":"16","author":"Sumnicht","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IAE.0000000000003404","article-title":"Acute exudative maculopathy and bacillary layer detachment in patients with central serous chorioretinopathy after photodynamic therapy","volume":"42","author":"Fern\u00e1ndez-Vigo","year":"2022","journal-title":"Retina"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/IAE.0000000000002343","article-title":"Photodynamic therapy-induced acute exudative maculopathy: incidence, clinical features, and long-term outcomes","volume":"40","author":"Manayath","year":"2020","journal-title":"Retina"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1038\/s41598-022-13208-y","article-title":"Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases","volume":"12","author":"Honda","year":"2022","journal-title":"Sci Rep"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/ICB.0000000000000356","article-title":"Incidence of acute exudative maculopathy after reduced-fluence photodynamic therapy","volume":"11","author":"Mammo","year":"2017","journal-title":"Retinal Cases Brief Rep"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.4103\/ijo.IJO_1077_18","article-title":"Management of chronic central serous chorioretinopathy","volume":"66","author":"Hanumunthadu","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"100865","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"R14-20250605","first-page":"14","article-title":"Pachychoroid disease","volume":"33","author":"Cheung","year":"2019","journal-title":"Eye (Basingstoke)"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1097\/IAE.0000000000003217","article-title":"Bacillary layer detachment: multimodal imaging and histologic evidence of a novel optical coherence tomography terminology: literature review and proposed theory","volume":"41","author":"Ramtohul","year":"2021","journal-title":"Retina"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"103107","DOI":"10.1016\/j.pdpdt.2022.103107","article-title":"Prediction of the response to photodynamic therapy in patients with chronic central serous chorioretinopathy based on optical coherence tomography using deep learning","volume":"40","author":"Fern\u00e1ndez-Vigo","year":"2022","journal-title":"Photodiagnosis Photodynamic Ther"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.jcjo.2016.08.001","article-title":"Atypical transient subretinal exudation following photodynamic therapy for chronic central serous retinopathy: a case report","volume":"52","author":"Al-Awadi","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"NP133","DOI":"10.1177\/11206721211027060","article-title":"Early vessel occlusion and recanalization after photodynamic therapy in central serous chorioretinopathy by OCT angiography","volume":"32","author":"Fern\u00e1ndez-Vigo","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1097\/IAE.0000000000003067","article-title":"Choroidal neovascularization secondary to photodynamic therapy for central serous chorioretinopathy: incidence, risk factors, and clinical outcomes","volume":"41","author":"Hwang","year":"2021","journal-title":"Retina"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3928\/23258160-20191119-03","article-title":"Long-term efficacy and safety of photodynamic therapy in patients with chronic central serous chorioretinopathy","volume":"50","author":"Park","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/IAE.0000000000001580","article-title":"Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy","volume":"38","author":"Bousquet","year":"2018","journal-title":"Retina"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamaophthalmol.2015.1320","article-title":"Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography","volume":"133","author":"Bonini Filho","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0002-9394(02)01438-1","article-title":"Retinal atrophy in idiopathic central serous chorioretinopathy11InternetAdvance publication at ajo.com Feb 28, 2002","volume":"133","author":"Wang","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/IAE.0b013e3182670fbe","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study","volume":"33","author":"Silva","year":"2013","journal-title":"Retina"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","article-title":"Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy","volume":"126","author":"Mrejen","year":"2019","journal-title":"Ophthalmology"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","article-title":"A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"170","author":"Lai","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/ph16040494","article-title":"Half-fluence, half-dose photodynamic therapy: less direct damage but more inflammation?","volume":"16","author":"Desmettre","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jcjo.2017.06.005","article-title":"Response to \u201cExudative complications following photodynamic therapy\u201d","volume":"52","author":"Somani","year":"2017","journal-title":"Can J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:08:46Z","timestamp":1749143326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003876","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}